IP Library Granted Patent US 8,512,743
Granted Patent B2
US 8,512,743 · App. 13/598,381 · Granted Aug 20, 2013

Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,512,743
App. No.
13/598,381
Granted
Aug 20, 2013
Kind
B2
Abstract

An apparatus for promoting the clotting of blood and controlling bleeding comprises a receptacle for retaining molecular sieve material in particulate form therein. A pad for controlling bleeding comprises a mesh structure and a rigid or semi-rigid support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. A bandage applicable to a bleeding wound comprises a mesh structure and a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attached to cover a wound. In any embodiment, at least a portion of the receptacle or mesh structure is defined by a mesh having openings therein, and at least a portion of the particulate molecular sieve material is in direct contact with blood.

Claims (45)

1. A device for promoting the clotting of blood comprising:

a pouch that is closed on all sides; and

a molecular sieve in particle form which is retained in the pouch;

wherein the pouch is composed of a mesh comprising a plurality of openings;

wherein the molecular sieve particles are configured to produce a diminished exothermic reaction upon contact with blood; and

wherein the molecular sieve particles are:

sufficiently large to be retained by the mesh; and

sufficiently small so that at least a portion of the particles can protrude through at least a portion of the openings of the mesh to make direct contact with blood outside of the pouch.

2. The device of claim 1 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the initial level of hydration of the molecular sieve particles.

3. The device of claim 1 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the particle size of the molecular sieve particles.

4. The device of claim 1 , wherein the molecular sieve comprises a zeolite.

5. The device of claim 4 , wherein the molecular sieve comprises an A-type zeolite.

6. The device of claim 1 , wherein the mesh comprises at least one of polyester, cotton, wool, or silk.

7. The device of claim 1 , wherein the particles have a diameter from about 2 mm to about 5 mm.

8. The device of claim 1 , further comprising at least one of the following materials or agents mixed with, associated with or incorporated into the molecular sieve: a pharmaceutically-active composition, an analgesic, an antibiotic, or an anti-inflammatory agent.

9. The device of claim 1 , further comprising sterile packaging within which the pouch is stored until the pouch is used.

10. The device of claim 1 , further comprising magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, a polysaccharide, silver ions or a compound containing silver ions, combinations of the foregoing materials, or hydrates of the foregoing materials.

11. The device of claim 1 , wherein the mesh is woven.

12. A method of accelerating the clotting of blood in a bleeding wound comprising:

providing an apparatus comprising:

providing a pouch that is closed on all sides;

providing a molecular sieve in particle form which is retained in the pouch; and

wherein the pouch is composed of a mesh comprising a plurality of openings;

wherein the molecular sieve particles are configured to produce a diminished exothermic reaction upon contact with blood; and

wherein the molecular sieve particles are:

sufficiently large to be retained by the mesh; and

sufficiently small so that at least a portion of the particles can protrude through at least a portion of the openings of the mesh to make direct contact with blood outside of the pouch;

applying the apparatus to the bleeding wound; and

maintaining the apparatus at the bleeding wound at least until blood from the wound begins to clot.

13. The method of claim 12 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the initial level of hydration of the molecular sieve particles.

14. The method of claim 12 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the particle size of the molecular sieve particles.

15. The method of claim 12 , further comprising applying pressure to the apparatus while the apparatus is applied to the bleeding wound.

16. The method of claim 12 , wherein the molecular sieve comprises an A-type zeolite.

17. The method of claim 12 , wherein the mesh comprises at least one of polyester, cotton, wool, or silk.

18. The method of claim 16 , further comprising at least one of the following materials or agents mixed with, associated with or incorporated into the molecular sieve: a pharmaceutically-active composition, an analgesic, an antibiotic, or an anti-inflammatory agent.

19. A method of manufacturing a hemostatic device, the method comprising:

providing a pouch that is closed on all sides; and

providing a molecular sieve in particle form which is retained in the pouch;

wherein the pouch is composed of a mesh comprising a plurality of openings;

wherein the molecular sieve particles are configured to produce a diminished exothermic reaction upon contact with blood ; and

wherein the molecular sieve particles are:

sufficiently large to be retained by the mesh; and

sufficiently small so that at least a portion of the particles can protrude through at least a portion of the openings of the mesh to make direct contact with blood outside of the pouch.

20. The method of claim 19 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the initial level of hydration of the molecular sieve particles.

21. The method of claim 19 , wherein configuring the molecular sieve particles to produce a diminished exothermic reaction comprises controlling the particle size of the molecular sieve particles.

Assignments (18)
SECURITY INTEREST Recorded Mar 1, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066723/0376 →
CHANGE OF NAME Recorded Feb 29, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066836/0737 →
MERGER Recorded Feb 29, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066707/0695 →
MERGER Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066621/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066616/0701 →
CHANGE OF NAME Recorded Feb 16, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066621/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066434/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: Z-MEDICA, LLC
To: TELEFLEX LIFE SCIENCES LIMITED
Reel/Frame 058740/0387 →
SECURITY INTEREST Recorded Mar 2, 2021
From: Z-MEDICA, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055455/0099 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2021
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: Z-MEDICA, LLC
Reel/Frame 054832/0770 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTENT OMISSION OF APPLICATION NO. 14/185873 FROM THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 044151 FRAME: 0282. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 22, 2020
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 054882/0904 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 035308/0704 Recorded Oct 9, 2017
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 044151/0282 →
SECURITY INTEREST Recorded Sep 29, 2017
From: Z-MEDICA, LLC
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 043738/0690 →
RELEASE AND REASSIGNMENT Recorded Apr 9, 2015
From: ABACUS FINANCE GROUP, LLC
To: Z-MEDICA, LLC
Reel/Frame 035389/0800 →
SECURITY INTEREST Recorded Apr 1, 2015
From: Z-MEDICA, LLC
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 035308/0704 →
MERGER Recorded Apr 1, 2015
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 035353/0423 →
SECURITY AGREEMENT Recorded Sep 6, 2012
From: Z-MEDICA, LLC
To: ABACUS FINANCE GROUP, LLC
Reel/Frame 028917/0898 →
MERGER Recorded Sep 4, 2012
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 028896/0108 →